Skip to Content
MilliporeSigma
All Photos(1)

Documents

1359404

USP

Levetiracetam

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(S)-(2-Oxopyrrolidin-1-yl)butyramide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H14N2O2
CAS Number:
102767-28-2
Molecular Weight:
170.21
MDL number:
MFCD03265610
UNSPSC Code:
41116107
PubChem Substance ID:
329750033
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

InChI key

HPHUVLMMVZITSG-LURJTMIESA-N

Gene Information

human ... CACNA1B(774) , SV2A(9900)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1359437

Levetiracetam Related Compound B, United States Pharmacopeia (USP) Reference Standard

1359415

Levetiracetam Racemic Mixture, United States Pharmacopeia (USP) Reference Standard

1359426

Levetiracetam Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001253

Levetiracetam, European Pharmacopoeia (EP) Reference Standard

Y0001256

Levetiracetam impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001254

Levetiracetam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001257

Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000659

Pyrrolidone, European Pharmacopoeia (EP) Reference Standard

Y0001962

Levetiracetam impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001948

Levetiracetam impurity G, European Pharmacopoeia (EP) Reference Standard

PHR2432

Levetiracetam Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2428

Levetiracetam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2417

Levetiracetam Racemic Mixture, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Bisoprolol fumarate United States Pharmacopeia (USP) Reference Standard

USP

1075757

Bisoprolol fumarate

Losartan Potassium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1602

Losartan Potassium

n-Hexane for liquid chromatography LiChrosolv®

Supelco

1.04391

n-Hexane

Valproic acid sodium salt 98%

Sigma-Aldrich

P4543

Valproic acid sodium salt

Gashirai K Mbizvo et al.
The Cochrane database of systematic reviews, 9(9), CD001901-CD001901 (2012-09-14)
Epilepsy is an important neurological condition and drug resistance in epilepsy is particularly common in individuals with focal seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as add-on treatment for controlling
Benjamin W Y Lo et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 38(3), 475-486 (2011-04-26)
New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile. To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent. Study Selection & Data Extraction: Eligible studies
Brian Longo et al.
The Annals of pharmacotherapy, 43(10), 1692-1695 (2009-08-20)
To review data evaluating levetiracetam management of epilepsy during pregnancy. A literature search of PubMed (1966-June 2009) was performed using the terms pregnancy, epilepsy, levetiracetam, and anticonvulsants. Bibliographies of all articles retrieved were reviewed to identify additional relevant articles. All
Amy Z Crepeau et al.
Expert review of neurotherapeutics, 10(2), 159-171 (2010-02-09)
Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small
Vincenzo Belcastro et al.
Brain & development, 33(4), 289-293 (2010-07-16)
Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service